Remedy

In June 2026, Remedy’s mix is dominated by Flower at 59.29% share, but the category posted a 72.17% year-over-year decline and a 30.47% month-over-month drop, pulling overall performance down alongside a 63rd rank in Flower within Nevada. Vapor Pens hold 21.47% share with a 27.00% year-over-year contraction and a sharper 33.81% month-over-month fall, while Concentrates at 14.72% share bucked the monthly slide with a 13.32% month-over-month increase despite a 49.11% year-over-year decline. Pre-Roll has thinned to 3.53% share after a 94.45% year-over-year and 42.87% month-over-month reduction, and Topical’s tiny 0.84% share carried a 198.72% year-over-year surge but a 66.19% month-over-month pullback. The pattern implies that Remedy’s exposure to two shrinking anchors—Flower and Vapor Pens—overwhelms smaller bright spots, concentrating risk in categories with steep year-over-year erosion.

These shifts point to a positioning pivot: the 13.32% month-over-month gain in Concentrates against double‑digit month-over-month drops in Flower (30.47%) and Vapor Pens (33.81%) suggests headroom in a lower-priced, value-accessible format, supported by an overall 34.30% average price lift year over year that may be pressuring high-ticket segments. With Flower still at 59.29% share and ranked 63rd in Nevada Flower, maintaining that weight likely prolongs decline, whereas reallocating mix toward Concentrates and pruning Pre-Roll after a 94.45% year-over-year collapse could reduce volatility. The implication is that Remedy’s defensible positioning in June 2026 is to de-emphasize premium-priced inhalables where price sensitivity is evident and lean into Concentrates as the stabilizer while testing small, low-risk bets in Topical given its 198.72% year-over-year lift despite a 66.19% month-over-month reset.